Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study
Background Blinatumomab, a bispecific T-cell engager, mediates cytotoxicity through CD3+ T-cell activation and has shown efficacy in relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although T-cell expansion correlates with favorable outcomes, routine immunophenotyping is impractica...